ARD-266

Cat. No.:	HY-133020		
CAS No.:	2666951-70-6		
Molecular Formula:	C ₅₂ H ₅₉ ClN ₆ O ₇		
Molecular Weight:	915.51		
Target:	PROTACs; Androgen Receptor		
Pathway:	PROTAC; Vitamin D Related/Nuclear Receptor		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (109.23 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	1.0923 mL	5.4614 mL	10.9229 mL		
		5 mM	0.2185 mL	1.0923 mL	2.1846 mL		
	10 mM	0.1092 mL	0.5461 mL	1.0923 mL			
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 5 mg/mL (5.46 mM); Suspended solution; Need ultrasonic						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 5 mg/mL (5.46 mM); Suspended solution; Need ultrasonic						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (5.46 mM); Clear solution						

BIOLOGICAL ACTIV	
Diologicality	
Description	ARD-266 is a highly potent and von Hippel-Lindau E3 ligase-based Androgen Receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC ₅₀ values of 0.2-1 nM ^[1] . ARD-266 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
IC ₅₀ & Target	VHL



In Vitro	 ARD-266 (Compound 11; 100 nM; 1-24 hours; LNCaP and VCaP cells) treatment effectively reduces the AR protein level within 3 h and achieves near-complete AR elimination with a 6 h treatment in the LNCaP cells^[1]. ARD-266 (Compound 11; 1-10000 nM; 24 hours; LNCaP cells) treatment effectively suppresses the expression of PSA, TMPRSS2, and FKBP5 genes in a dosedependent manner and is capable of reducing the mRNA levels of PSA, TMPRSS2, and FKBP5 genes by >50% at 10 nM in the LNCaP cell line^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis^[1] 				
	Cell Line:	LNCaP and VCaP cells			
	Concentration:	100 nM			
	Incubation Time:	1 hour, 3 hours, 6 hours, 12 hours, 24 hours			
	Result:	Effectively reduced the AR protein level within 3 h and achieved near-complete AR elimination with a 6 h treatment in the LNCaP cells.			
	RT-PCR ^[1]				
	Cell Line:	LNCaP cells			
	Concentration:	1 nM, 10 nM, 100 nM, 1000 nM, 10000 nM			
	Incubation Time:	24 hours			
	Result:	Effectively suppressed the expression of PSA, TMPRSS2, and FKBP5 genes in a dose- dependent manner and was capable of reducing the mRNA levels of PSA, TMPRSS2, and FKBP5 genes by >50% at 10 nM in the LNCaP cell line.			

REFERENCES

[1]. Han X, et al. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019 Dec 26;62(24):11218-11231.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA